Zobrazeno 1 - 5
of 5
pro vyhledávání: '"35"'
Autor:
Apurvasena Parikh, Colin D. Weekes, Monica Motwani, Daniel Morgensztern, Huibin Yue, Edward B. Reilly, John Nemunaitis, Todd M. Bauer, Ramesh K. Ramanathan, Daniel E. H. Afar, Rebecca S. Heist, Karen Kelly, Eric Angevin, John H. Strickler, Louie Naumovski
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 33
Strickler, JH; Weekes, CD; Nemunaitis, J; Ramanathan, RK; Heist, RS; Morgensztern, D; et al.(2018). First-in-Human Phase I, Dose-Escalation and-Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018787697. doi: 10.1200/jco.2018.78.7697. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bt41691
Strickler, JH; Weekes, CD; Nemunaitis, J; Ramanathan, RK; Heist, RS; Morgensztern, D; et al.(2018). First-in-Human Phase I, Dose-Escalation and-Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2018787697. doi: 10.1200/jco.2018.78.7697. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/8bt41691
Purpose This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody–drug conjugate of the anti–c-Met monoclonal antibody ABT-700 and monomethyl auristatin E. Materials and Methods For dose escalatio
Autor:
William C. Wood, Fengmin Zhao, Vicky Jones, Silvana Martino, Nancy E. Davidson, Vered Stearns, Molin Wang, Tom Saphner, George W. Sledge, Joseph A. Sparano, Edith A. Perez, Bryan P. Schneider, Antonio C. Wolff
Publikováno v:
Journal of Clinical Oncology. 30:3051-3057
Purpose Neuropathy is a common and potentially disabling complication of adjuvant taxane therapy. Recent studies have identified candidate single nucleotide polymorphisms associated with taxane-induced neuropathy. Therefore, we sought to determine wh
Autor:
Moacyr Ribeiro de Oliveira, D. Ross Camidge, Elizabeth Litvinovich, Yi-Lin Chiu, Cathy E. Nolan, Charles M. Rudin, Divis Khaira, Geoffrey I. Shapiro, Todd A. Busman, Hao Xiong, Caroline Dive, David R. Gandara, Evelyn McKeegan, Philip Bonomi, Sari H. Enschede, Rod A. Humerickhouse, Andrew Krivoshik, Leena Gandhi, Philip M. Hemken, Christine L. Hann
Publikováno v:
Journal of Clinical Oncology. 29:909-916
Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel in
Autor:
Ana Lluch, Monica Fornier, David Lebwohl, Edgardo Rivera, Linda T. Vahdat, Patrice Viens, José Baselga, Eva Thomas, Valentina Guarneri, Valerie Poulart, Josep Tabernero, J. Klimovsky, Pierfranco Conte, Howard A. Burris, Miguel Martin, Craig A. Bunnell, Pierre Fumoleau
Publikováno v:
Journal of Clinical Oncology. 25:3399-3406
Purpose Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring epothilone B. Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing apo
Autor:
Peter G. Rose, Gertrude Peterson, Nancy Fusco, Jerome L. Belinson, Maurie Markman, Alexander W. Kennedy, Ira R. Horowitz, Kenneth Webster, Elizabeth Jones, Lisa Fluellen, William P. McGuire, Barb Kulp
Publikováno v:
Journal of Clinical Oncology. 16:1849-1851
PURPOSE To test the hypothesis that prolonged infusion of paclitaxel (96 hours) might overcome resistance to shorter infusion schedules (3 or 24 hours) in ovarian cancer. PATIENTS AND METHODS A total of 30 patients with advanced ovarian cancer (24 pa